The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Ragini Reiney Kudchadkar
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Geoffrey Thomas Gibney
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Bin Yu
No relevant relationships to disclose
PingYan Cheng
No relevant relationships to disclose
Alberto J Martinez
No relevant relationships to disclose
Jodi Kroeger
No relevant relationships to disclose
Donna Gallenstein
No relevant relationships to disclose
Allison Richards
No relevant relationships to disclose
Eric Welsh
No relevant relationships to disclose
Xiuhua Zhao
No relevant relationships to disclose
Xiaotao Qu
No relevant relationships to disclose
Ann Chen
No relevant relationships to disclose